Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

(2014) T. Koudriavtseva et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab

(2014) Xenia Kobeleva et al.   Journal of Neuroinflammation

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

(2014) Dean M. Wingerchuk et al.   MAYO CLINIC PROCEEDINGS

Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis

(2013) Klaus Jansen et al.   BMC INFECTIOUS DISEASES

Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients

(2013) A. J. Fine et al.   CLINICAL INFECTIOUS DISEASES

Report of Three Cases of Herpes Zoster During Treatment with Natalizumab

(2013) Yara Dadalti Fragoso et al.   CNS Neuroscience & Therapeutics

Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab

(2013) B. Bourre et al.   NEUROLOGY

Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab

(2013) J. Yeung et al.   NEUROLOGY

T-cell response against varicella-zoster virus in fingolimod-treated MS patients

(2013) M. E. Ricklin et al.   NEUROLOGY

Herpes Zoster Among Persons Living With HIV in the Current Antiretroviral Therapy Era

(2012) Leah J. Blank et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

(2012) J. N. Ratchford et al.   NEUROLOGY

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab and HSV meningitis

(2011) Erica Seiguer Shenoy et al.   JOURNAL OF NEUROVIROLOGY

Subclinical reactivation of varicella zoster virus in all stages of HIV infection

(2011) Marius Birlea et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Herpes encephalitis during natalizumab treatment in multiple sclerosis

(2011) A Kwiatkowski et al.   Multiple Sclerosis Journal

Progressive multifocal leukoencephalopathy: clinical and molecular aspects

(2011) Eleonora Tavazzi et al.   REVIEWS IN MEDICAL VIROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies

(2010) G N Malavige et al.   BRITISH JOURNAL OF CANCER

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine

(2009) Adriana Weinberg et al.   JOURNAL OF INFECTIOUS DISEASES

Symptomatology of MS: results from the German MS Registry

(2009) Kristin Stuke et al.   JOURNAL OF NEUROLOGY